Literature DB >> 17917545

Targets of anticytokine therapy and the risk of infections in humans and mice.

Esther van de Vosse1, Michiel A van Agtmael.   

Abstract

PURPOSE OF REVIEW: To examine the type and risk of infections in humans and mice deficient in proinflammatory cytokines. Naturally occurring or manipulated genetic defects of tumor necrosis factor, interleukins-1, -6, -12, and -15, and interferon-gamma are examined for their increased susceptibility to, or protection from, infection. RECENT
FINDINGS: Interleukin-12p40 and interferon-gamma-blockers may lead to increased incidence of infections with intracellular bacteria, parasites, and fungi. In addition, we may see viral infections with interferon-gamma-blockers. Increased risk of infections is unlikely with either interleukin-1- or interleukin-15-blockers. Interleukin-6-blockers may lead to increased risk of infection with extracellular bacteria, viruses, parasites and fungi.
SUMMARY: In tumor necrosis factor knockout mice, increased susceptibility to pathogens are reported that are normally controlled by granuloma formation. In patients treated with tumor necrosis factor-blockers, a two-fold increase of granulomatous infections, predominantly reactivation of latent tuberculosis, is found. The infections detected in tumor necrosis factor knockout mice were accurate for predicting the infections observed when using tumor necrosis factor-blockers. If a similar correlation exists for other cytokines, the use of interferon-gamma and interleukin-12p40 blockers, and possibly interleukin-6 blockers, will lead to an increased risk for severe infections. Care should be taken when new cytokine blockers/antagonists are introduced.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917545     DOI: 10.1097/BOR.0b013e3282f05c6d

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  7 in total

Review 1.  Infectious complications associated with monoclonal antibodies and related small molecules.

Authors:  Edsel Maurice T Salvana; Robert A Salata
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

Review 2.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

3.  TLR4 ligands induce IFN-alpha production by mouse conventional dendritic cells and human monocytes after IFN-beta priming.

Authors:  Christophe Richez; Kei Yasuda; Amanda A Watkins; Shizuo Akira; Robert Lafyatis; Jean M van Seventer; Ian R Rifkin
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

Review 4.  Manipulation of the hepcidin pathway for therapeutic purposes.

Authors:  Eileen Fung; Elizabeta Nemeth
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

Review 5.  Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.

Authors:  Jing Liu; Bingbing Sun; Huijun Yin; Sijin Liu
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 6.  Hepcidin and sports anemia.

Authors:  Wei-Na Kong; Guofen Gao; Yan-Zhong Chang
Journal:  Cell Biosci       Date:  2014-04-14       Impact factor: 7.133

7.  Mechanistic and Structural Insights on the IL-15 System through Molecular Dynamics Simulations.

Authors:  Rui P Sousa; Adèle D Laurent; Agnès Quéméner; Erwan Mortier; Jean-Yves Le Questel
Journal:  Molecules       Date:  2019-09-06       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.